Domain licenses Parkinson's drug candidates to Merck Serono spinoff

01/24/2013 | Genetic Engineering & Biotechnology News

Merck Serono spinoff Prexton Therapeutics was given an exclusive option by Domain Therapeutics to advance through clinical development stage its metabotropic glutamate receptor 4-positive allosteric modulator drug candidates against Parkinson's disease. The chemical series emerged from joint work by Domain and Merck Serono.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC